1
|
Minegishi G, Kazuki Y, Nitta SI, Miyajima A, Akita H, Kobayashi K. In vivo evaluation of intestinal human CYP3A inhibition by macrolide antibiotics in CYP3A-humanised mice. Xenobiotica 2021; 51:764-770. [PMID: 34013847 DOI: 10.1080/00498254.2021.1921314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
It is important to predict drug-drug interactions via inhibition of intestinal cytochrome P450 3A (CYP3A) which is a determinant of bioavailability of orally administered CYP3A substrates. However, inhibitory effects of macrolide antibiotics on CYP3A-mediated metabolism are not entirely identical between humans and rodents.We investigated the effects of macrolide antibiotics, clarithromycin and erythromycin, on in vitro and in vivo metabolism of triazolam, a CYP3A substrate, in CYP3A-humanised mice generated by using a mouse artificial chromosome vector carrying a human CYP3A gene.Metabolic activities of triazolam were inhibited by macrolide antibiotics in liver and intestine microsomes of CYP3A-humanised mice.The area under the plasma concentration-time curve ratios of 4-hydroxytriazolam to triazolam after oral dosing of triazolam were significantly decreased by multiple administration of macrolide antibiotics. The plasma concentrations ratios of α-hydroxytriazolam and 4-hydroxytriazolam to triazolam in portal blood were significantly decreased by multiple administration of clarithromycin in CYP3A-humanised mice.These results suggest that intestinal CYP3A activity was inhibited by macrolide antibiotics in CYP3A-humanised mice in vitro and in vivo. The plasma concentrations of triazolam and its metabolites in the portal blood of CYP3A-humanised mice would be useful for direct evaluation of intestinal CYP3A-mediated drug-drug interactions.
Collapse
Affiliation(s)
- Genki Minegishi
- Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
| | - Yasuhiro Kazuki
- Chromosome Engineering Research Center (CERC), Tottori University, Tottori, Japan.,Department of Molecular and Cellular Biology, Division of Genome and Cellular Functions, Faculty of Medicine, School of Life Science, Tottori University, Tottori, Japan
| | - Shin-Ichiro Nitta
- Bioanalysis Department, Medical Solution Segment, Advanced Technology Center, LSI Medience Corporation, Tokyo, Japan
| | - Atsushi Miyajima
- Department of Biopharmaceutics, Graduate School of Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan
| | - Hidetaka Akita
- Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
| | - Kaoru Kobayashi
- Department of Biopharmaceutics, Graduate School of Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan
| |
Collapse
|
2
|
Haarhoff ZE, Kramer MA, Zvyaga TA, Zhang J, Bhutani P, Subramanian M, Rodrigues AD. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human. Xenobiotica 2016; 47:470-478. [DOI: 10.1080/00498254.2016.1203042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
| | | | | | - Jun Zhang
- Bristol-Myers Squibb, Wallingford, CT, USA,
| | - Priyadeep Bhutani
- Biocon Bristol-Myers Squibb Research and Development Center, Syngene International Limited, Bangalore, Karnataka, India
| | - Murali Subramanian
- Biocon Bristol-Myers Squibb Research and Development Center, Syngene International Limited, Bangalore, Karnataka, India
| | | |
Collapse
|
3
|
Takahashi T, Ohtsuka T, Yoshikawa T, Tatekawa I, Uno Y, Utoh M, Yamazaki H, Kume T. Pitavastatin as an In Vivo Probe for Studying Hepatic Organic Anion Transporting Polypeptide-Mediated Drug–Drug Interactions in Cynomolgus Monkeys. Drug Metab Dispos 2013; 41:1875-82. [DOI: 10.1124/dmd.113.052753] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
|
4
|
Alreja G, Inayatullah S, Goel S, Braden G. Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin. J Cardiovasc Dis Res 2012; 3:319-22. [PMID: 23233778 PMCID: PMC3516014 DOI: 10.4103/0975-3583.102720] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Rhabdomyolysis is an uncommon but life-threatening adverse effect of simvastatin therapy. A 73-year-old male on chronic simvastatin therapy received azithromycin for acute bronchitis. He presented with weakness of all extremities with a significant increase in creatinine phosphokinase levels and acute kidney injury. Simvastatin was stopped and supportive therapy with intravenous saline and bicarbonate was initiated. The serum creatinine and creatine phosphokinase returned to baseline in the next 7 days. Two months later, simvastatin was resumed without any recurrence of symptoms. Our case report highlights the rare description of rhabdomyolysis caused by a drug interaction between simvastatin with azithromycin.
Collapse
Affiliation(s)
- Gaurav Alreja
- Department of Medicine, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
| | | | | | | |
Collapse
|
5
|
Kanazu T, Sato N, Kadono K, Touchi A, Takeda Y, Yamaguchi Y, Baba T. Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats. Biopharm Drug Dispos 2012; 33:195-206. [DOI: 10.1002/bdd.1785] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2011] [Revised: 02/21/2012] [Accepted: 03/20/2012] [Indexed: 11/09/2022]
Affiliation(s)
- Takushi Kanazu
- Drug Metabolism and Pharmacokinetics, Drug Developmental Research Laboratories; Shionogi & Co., Ltd; Toyonaka; Osaka; Japan
| | - Norihito Sato
- Drug Metabolism and Pharmacokinetics, Drug Developmental Research Laboratories; Shionogi & Co., Ltd; Toyonaka; Osaka; Japan
| | - Kyoko Kadono
- Drug Metabolism and Pharmacokinetics, Drug Developmental Research Laboratories; Shionogi & Co., Ltd; Toyonaka; Osaka; Japan
| | - Akira Touchi
- Drug Metabolism and Pharmacokinetics, Drug Developmental Research Laboratories; Shionogi & Co., Ltd; Toyonaka; Osaka; Japan
| | - Yuri Takeda
- Drug Metabolism and Pharmacokinetics, Drug Developmental Research Laboratories; Shionogi & Co., Ltd; Toyonaka; Osaka; Japan
| | - Yoshitaka Yamaguchi
- Drug Metabolism and Pharmacokinetics, Drug Developmental Research Laboratories; Shionogi & Co., Ltd; Toyonaka; Osaka; Japan
| | - Takahiko Baba
- Drug Metabolism and Pharmacokinetics, Drug Developmental Research Laboratories; Shionogi & Co., Ltd; Toyonaka; Osaka; Japan
| |
Collapse
|
6
|
Sekiguchi N, Kato M, Takada M, Watanabe H, Takata S, Mitsui T, Aso Y, Ishigai M. Quantitative Prediction of Mechanism-Based Inhibition Caused by Mibefradil in Rats. Drug Metab Dispos 2011; 39:1255-62. [DOI: 10.1124/dmd.110.037903] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
7
|
Ohtsuka T, Yoshikawa T, Kozakai K, Tsuneto Y, Uno Y, Utoh M, Yamazaki H, Kume T. Alprazolam as an In Vivo Probe for Studying Induction of CYP3A in Cynomolgus Monkeys. Drug Metab Dispos 2010; 38:1806-13. [DOI: 10.1124/dmd.110.032656] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
|
8
|
Tang C, Prueksaritanont T. Use of in vivo animal models to assess pharmacokinetic drug-drug interactions. Pharm Res 2010; 27:1772-87. [PMID: 20428930 DOI: 10.1007/s11095-010-0157-z] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Accepted: 04/08/2010] [Indexed: 12/31/2022]
Abstract
Animal models are used commonly in various stages of drug discovery and development to aid in the prospective assessment of drug-drug interaction (DDI) potential and the understanding of the underlying mechanism for DDI of a drug candidate. In vivo assessments in an appropriate animal model can be very valuable, when used in combination with in vitro systems, to help verify in vivo relevance of the in vitro animal-based results, and thus substantiate the extrapolation of in vitro human data to clinical outcomes. From a pharmacokinetic standpoint, a key consideration for rational selection of an animal model is based on broad similarities to humans in important physiological and biochemical parameters governing drug absorption, distribution, metabolism or excretion (ADME) processes in question for both the perpetrator and victim drugs. Equally critical are specific in vitro and/or in vivo experiments to demonstrate those similarities, usually both qualitative and quantitative, in the ADME properties/processes under investigation. In this review, theoretical basis and specific examples are presented to illustrate the utility of the animal models in assessing the potential and understanding the mechanisms of DDIs.
Collapse
Affiliation(s)
- Cuyue Tang
- Department of Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, Merck & Co., Inc., WP75A-203, West Point, Pennsylvania 19486, USA
| | | |
Collapse
|